The clinical utility of immunohistochemistry (IHC) for detecting the expression of PD-L1 on tumor cells and/or tumor-infiltrating immune cells was confirmed initially in the first clinical study of the anti-PD-1 drug nivolumab and subsequently in other studies. Here, CD274 is linked to neoplasm.